About Splicing factor 3A subunit 3
Splicing factor 3A subunit 3 (SF3A3) is a protein
from Homo sapiens identified by UniProt accession
Q12874, 501 residues long.
MolForge cross-references it against 0 known binders and
57 disease associations.
Target properties
| Protein name | Splicing factor 3A subunit 3 |
| UniProt accession | Q12874 |
| Gene | SF3A3 |
| Organism | Homo sapiens |
| Length | 501 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (57)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- heel bone mineral density · score 0.25
- lean body mass · score 0.24
- appendicular lean mass · score 0.22
- coronary artery disease · score 0.21
- body height · score 0.20
- bone quantitative ultrasound measurement · score 0.19
- balding measurement · score 0.19
- colorectal cancer · score 0.19
- pulse pressure measurement · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q12874-F1 | alphafold | PREDICTED | 86.23 | — |
Amino-acid sequence (501 residues)
METILEQQRR YHEEKERLMD VMAKEMLTKK STLRDQINSD HRTRAMQDRY MEVSGNLRDL YDDKDGLRKE ELNAISGPNE FAEFYNRLKQ IKEFHRKHPN EICVPMSVEF EELLKARENP SEEAQNLVEF TDEEGYGRYL DLHDCYLKYI NLKASEKLDY ITYLSIFDQL FDIPKERKNA EYKRYLEMLL EYLQDYTDRV KPLQDQNELF GKIQAEFEKK WENGTFPGWP KETSSALTHA GAHLDLSAFS SWEELASLGL DRLKSALLAL GLKCGGTLEE RAQRLFSTKG KSLESLDTSL FAKNPKSKGT KRDTERNKDI AFLEAQIYEY VEILGEQRHL THENVQRKQA RTGEEREEEE EEQISESESE DEENEIIYNP KNLPLGWDGK PIPYWLYKLH GLNINYNCEI CGNYTYRGPK AFQRHFAEWR HAHGMRCLGI PNTAHFANVT QIEDAVSLWA KLKLQKASER WQPDTEEEYE DSSGNVVNKK TYEDLKRQGL L
Explore Splicing factor 3A subunit 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets